Beam Therapeutics Inc.

Beam Therapeutics is one of the two public leaders in DNA base-editing — a next-generation gene therapy approach that rewrites individual DNA letters rather than cutting the double helix. It has no meaningful revenue yet, and the whole equity is a bet on the platform, and specifically on David Liu.

How to read the setup:

• Revenue still tiny vs market cap: Q1 revenue was $31.7M against a $2.8B market cap — trailing revenue up 3x YoY but off a very small base; trailing P/S of 18x is meaningless for a clinical-stage biotech.
• Cash burn is the real number: operating margin -338% last quarter, FCF yield -13% — lower R&D would slow the platform, higher triggers dilution; the shelf timing is what to watch.
• Bull case rests on founder and platform: David Liu is arguably the most productive academic biologist in modern gene-editing; 'PRME 25% annual returns for 20 years' is bet-the-jockey framing, not bet-the-P&L.
• Price action is quietly constructive: 65th percentile of the 52-week range, 2% above the 50-day, 8% above the 200-day, on 68% of baseline volume — no chase, no distribution, base-forming.
• The $BEAM chatter partly hits a crypto token — treat the crypto side as ticker collision; the equity signal is the David Liu framing.

The November 3 print defends the setup — pipeline milestones (BEAM-101 in sickle cell, BEAM-302 in AATD) plus any partnering activity keeps the platform bet alive; a fresh equity raise or clinical setback breaks the coil to the mid-$20s.